

International Journal of Cancer and Treatment

Int J Cancer Treat 2019

Management of stage I and II non-small cell lung cancer

Ashish Dolas Shilpy Dolas Associate professor. Dept. of CVTS, D.Y Patil Medical College, Hospital and Research Centre, Pune
Consultant Oncoplastic surgeon, Ruby Hall Clinic, Pune

The incidence of stage I and II non small cell lung cancer is likely to increase with the ageing population and introduction of screening for high-risk individuals. Optimal management requires multidisciplinary collaboration. Local treatments include surgery and radiotherapy and these are currently combined with (neo)adjuvant chemotherapy in specific cases to improve long-term outcome.

Targeted therapies and immunotherapy may also become important therapeutic modalities in this patient group. For resectable disease in patients with low cardiopulmonary risk, complete surgical resection with lobectomy remains the gold standard.

Minimally invasive techniques, conservative and sublobar resections are suitable for a subset of patients.

Data are emerging that radiotherapy, especially stereotactic body radiation therapy, is a valid alternative in compromised patients who are high-risk candidates for surgery.

Whether this is also true for good surgical candidates remains to be evaluated in randomised trials. In specific subgroups adjuvant chemotherapy has been shown to prolong survival; however, patient selection remains important.

Neoadjuvant chemotherapy may yield similar results as adjuvant chemotherapy. The role of targeted therapies and immunotherapy in early stage nonsmall cell lung cancer has not yet been determined and results of randomised trials are awaited.

Article Information

Conferenc Proceedings: World Congress On Cancer Science and Therapy (Bangkok)

Conferecne date: 02-03 December, 2019

Inovineconferences.com

*Corresponding author: Ashish Dolas, Associate professor. Dept. of CVTS, D.Y Patil Medical College, Hospital and Research Centre, Pune.

Citation: Dolas A, Dolas S (2019) Effect of Bortezomib in L1210 Cells. Int J Cancer Treat.

Copyright: © 2019 Dolas A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.